CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Liso-Cel Induces High Rate of Durable Responses in LBCL

December 9th 2019

CD19-directed CAR T-cell therapy induced a high rate of rapid and durable complete responses in patients with aggressive relapsed/refractory large B-cell lymphoma.

Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma

December 8th 2019

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

CAR-T Progress Continues in Non-Hodgkin Lymphoma, But Guidelines Need Updating

December 3rd 2019

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Dr. Perales on CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 3rd 2019

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

Dr. Garfall Discusses CAR T-Cell Therapy in Multiple Myeloma

November 22nd 2019

Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.

Dr. Perales on Ongoing Studies With CAR T Cells in DLBCL

November 16th 2019

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Park on Updates With CAR T Cells in ALL

November 1st 2019

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Shah on CAR T-Cell Therapy in Pediatric ALL

October 10th 2019

Nirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.

Dr. Sasine on Predicting Individual Benefit with CAR T Cells

October 9th 2019

Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.

Improving CAR T-Cell Therapies With Greater Understanding of Cancer Immunology

October 8th 2019

Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence.

Dr. Sotomayor on the Durability of CAR T Cells in Hematologic Malignancies

October 4th 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease

September 28th 2019

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

Dr. Frey on CAR T-Cell Therapy in High-Risk ALL

September 27th 2019

Noelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.

Dr. Marasco on Engineering CAR T Cells

September 25th 2019

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

CAR T Cells Could Revolutionize RCC Treatment

September 23rd 2019

Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.

Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL

September 21st 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Dr. Sotomayor on Differences Between FDA-Approved CAR T-Cell Therapies

September 21st 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

Sasine Highlights Strides With CAR T-Cell Therapy in Hematologic Cancers

September 16th 2019

Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.

Tisagenlecleucel Maintains Efficacy in Real-World Setting

September 15th 2019

Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

September 14th 2019

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.